Skip Navigation


Rheumatology Advance Access originally published online on March 20, 2008
Rheumatology 2008 47(5):656-659; doi:10.1093/rheumatology/ken092
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
47/5/656    most recent
ken092v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Koivula, M.-K.
Right arrow Articles by Risteli, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koivula, M.-K.
Right arrow Articles by Risteli, J.
Related Collections
Right arrow Spondylarthropathies
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Sensitivity and specificity of autoantibodies binding to citrullinated carboxyterminal telopeptides of types I and II collagens in an early arthritis series

M.-K. Koivula1,2, E. Savolainen3, O. Kaipiainen-Seppänen4, H. Kautiainen5, R. Luosujärvi6, M. Hakala7,8 and J. Risteli1

1Department of Clinical Chemistry, University of Oulu, Oulu, 2Turku University Central Hospital, Turku, 3Kuopio Municipal Hospital, Kuopio, 4Department of Medicine, Kuopio University Hospital, Kuopio, 5MedCare Foundation, Äänekoski, 6Department of Medicine, Helsinki University Central Hospital, Helsinki, 7Rheumatism Foundation Hospital, Heinola and 8Department of Musculoskeletal Medicine and Rehabilitation, Medical School, University of Tampere, Tampere, Finland.

Correspondence to: J. Risteli, Department of Clinical Chemistry, P.O.Box 5000, FI-90014 University of Oulu, Oulu, Finland. E-mail: juha.risteli{at}oulu.fi


  Abstract

Objective. To assess the specificity and sensitivity of autoantibodies binding to citrullinated carboxyterminal telopeptides of types I and II collagens in an early arthritis series.

Methods. A cohort of 146 patients from the Kuopio 2000 Arthritis Survey having RA, AS, PsA, ReA, uSpA or undifferentiated arthritis were studied. Autoantibodies binding citrullinated types I and II carboxytelopeptides were measured in two different inhibition ELISA assays. Sera from 135 adult persons were used as controls.

Results. In RA, the sensitivities were 0.83 with long type I telopeptide and 0.78 with long type II telopeptide and the respective specificities were 0.94 and 0.93, while the corresponding values in other inflammatory joint diseases were much lower. The likelihood ratio in RA increased with longer peptides from 4.20 to 14.06 for type I telopeptide and from 2.74 to 11.67 for type II telopeptide.

Conclusion. The antibody assay using long telopeptide from type I collagen was the most specific and sensitive method in every diagnostic category, although in the arthritides other than RA, binding was much less abundant and possibly citrulline-independent.

KEY WORDS: Anti-CCP antibodies, Autoantibodies, Citrullination, Early arthritis, RA, SpA, Telopeptide, Type I collagen, Type II collagen

Submitted 30 August 2007; revised version accepted 6 February 2008.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.